Below is the SPLIT/NASPGHAN COVID registry Week Week 10 report: 4 new cases have been added including one patient with acute liver failure (pre-transplant)

• There are 41 COVID positive patients: 21 with liver disease non-transplant and 20 post-liver transplant recipients
• 34 have recovered and 6 are still active in their clinical course or pending further updates
• 1 death has been reported, described by Dr. Hildreth on this listserv
• Reported complications of chronic liver disease during COVID infection include: ascites in 6 patients, variceal bleeding in 1 patient and infection in 1 patient; all with chronic liver disease

Click the button below for the SPLIT/NASPGHAN COVID registry Week 9 report: 2 new cases have been added

• There are 37 COVID positive patients: 19 with chronic liver disease, 18 post-liver transplant recipients
• 31 have recovered and 5 are still active in their clinical course or pending further updates
• 1 death has been reported, described by Dr. Hildreth on this listserv
• Reported complications of chronic liver disease during COVID infection include: ascites in 5 patients, variceal bleeding in 1 patient; all with chronic liver disease

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 8 report: 3 new cases have been added

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 7 report: 2 new cases have been added

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 6 report: 2 new cases have been added

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 5 report: 7 new cases have been added

CLick the button below for the SPLIT/NASPGHAN COVID registry Week 4 report: 6 new cases have been added

• There are 23 COVID positive patients: 14 with chronic liver disease, 9 post-liver transplant recipients
• 13 have recovered and 10 are still active in their clinical course or pending further updates
• 2 patients with chronic liver disease required mechanical ventilation or HFOV
• One patient who remains critically ill with NAFLD has required intubation, pressor support, CRRT and received COVID directed therapies (azithromycin and hydroxychloroquine, remdesivir, convalescent plasma, tocilizumab, steroids and eculizumab)
• No deaths have been reported
• Reported complications of chronic liver disease during COVID infection include: ascites in 4 patients, variceal bleeding in 1 patient and infection in 1 patient

Below is the SPLIT/NASPGHAN COVID registry Week 3 report: 6 new cases have been added

• There are 17 COVID positive patients: 9 with chronic liver disease, 8 post-liver transplant recipients
• 13 have recovered and 4 are still active in their clinical course
• 1 patient with chronic liver disease required mechanical ventilation
• Reported complications of chronic liver disease during COVID infection include: ascites in 3 patients and variceal bleeding in 1 patient
• No deaths were reported
• COVID directed therapies included: hydroxychloroquine, azithromycin, IVIG, tocilizumab + sarilumab

Below is the SPLIT/NASPGHAN COVID registry Week 2 report:

7 new cases have been added

• There are 11 COVID positive patients: 4 with chronic liver disease, 7 post-liver transplant recipients
• 9 have recovered and 2 are still active in their clinical course
• No patients required mechanical ventilation
• No deaths were reported
• 1 patient received COVID directed therapy with azithromycin

Below is the first week’s report for the SPLIT/NASPGHAN COVID registry which includes 4 total COVID positive patients. This includes:

• 2 pediatric patients with chronic liver disease (biliary atresia and AIH)
• 2 patients s/p liver transplant (for biliary atresia and ALF)

Of the above 4 patients:

• 2 have clinically recovered and 2 are still active in their clinical course
• One patient with biliary atresia s/p liver transplant who was <1 year out from transplant had tacrolimus trough levels reduced. The other patient who was >5 years out from liver transplant had no changes to their immunosuppression
• Of the patients with chronic liver disease: one patient with autoimmune hepatitis had their dosage of azathioprine reduced, the other patient with biliary atresia was not any immunosuppressive therapies
• None of the 4 patients received COVID directed treatment (for example: azithromycin, remdesivir, etc)